Recent

% | $
Quotes you view appear here for quick access.

Intellect Neurosciences, Inc. Message Board

  • prophetmontanus prophetmontanus Jul 31, 2013 3:12 PM Flag

    Ponezumab - Phase 2 Clinical trial

    Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

    This study is currently recruiting participants

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good post. I like real information. I worry that if anyone is just looking at this message board that is monopolized by a single person with multiple aliases they don't get a true picture of the companies potential. I suggest that anyone who wants more info take a look at the posts on ihub.

    • Intellect Neurosciences Announces New Findings Supporting its Patented ANTISENILIN Platform Technology for the Treatment of Alzheimer's Disease

      New Publication Demonstrates Safety and Efficacy in Reducing Brain Amyloid in Preclinical Model

      NEW YORK, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, announced today new findings on ponezumab (PF-04360365), an investigational anti-amyloid beta monoclonal antibody that specifically targets the neoepitope at the C-terminus of the peptide, published in the October 2012 edition of Current Alzheimer Research.

      These new data describe the properties of a version of ponezumab in which naturally occurring sugar bound to the surface of the murine antibody was removed to improve the safety of the drug. The aglycosylated murine surrogate of ponezumab was administered by intraperitoneal injection once weekly for up to 26 weeks at doses of 0, 10, 30, or 100 mg/kg. Drug exposure and plasma amyloid beta levels increased with increasing dose. After 26 weeks, the 100mg/kg group had significantly greater plasma levels of A1-x and Ax-40 than the vehicle group (p

      • 1 Reply to prophetmontanus
      • "We are encouraged by these data supporting our belief that antibodies targeting soluble forms of A beta can be beneficial in treating AD patients. This idea is consistent with results from the solanezumab Phase 3 clinical trials, which showed a modest but consistent clinical benefit from reducing A beta monomers in the brain. That data has positive implications for the important therapeutic potential of ponezumab, as well of Intellect's internal pipeline of A beta-specific antibodies, including 1A10 (targets the C terminus of A beta at position 40), IC3 (targets the C-terminus of A beta at position 42) and 82E1 (aka IN-N01, targets the N-terminus)," stated Daniel Chain, PhD, chairman and CEO of Intellect. "We have been granted several patents by the USPTO in relation to these antibodies any of which could be developed singly or empowered with additional neuroprotective function under our CONJUMAB platform."

        Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.

 
ILNS
0.33990.0000(0.00%)Apr 30 3:33 PMEDT